Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
Year: 2026
Type: article
Abstract: Not available.
Source: Haematologica
Authors: Guillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, Alexandre Iat, Amel Soua, Daniel J. DeAngelo, Leora Boussi, Rory M. Shallis, Andrius Žučenka, Rebecca P. Bystrom, Kelly Ling, Luis E. Aguirre, Richard M. Stone, Marlise R. Luskin, Jacqueline S. Garcia, Eric S. Winer, Evan C. Chen, Martha Wadleigh, Lourdes Mendez, Nikolai Podoltsev, Urbain Tauveron-Jalenques, Luca Lanino, Eytan Stein, Amer M. Zeidan, Edouard Forcade, Thomas Cluzeau, Pierre-Yves Dumas, Mael Heiblig, Raynier Devillier, Shai Shimony, Aaron D. Goldberg, Maximilian Stahl, Sylvain Garciaz
Institutions: Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Yale University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Vilnius University, Vilnius University Hospital Santariskiu Klinikos, Duke Medical Center, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Hospitalier Universitaire de Bordeaux, Immunology from Concept and Experiments to Translation, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Université de Bordeaux, BoRdeaux Institute of onCology, Hospices Civils de Lyon, Hôpital Lyon Sud
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Gilead Sciences, Alexion Pharmaceuticals, Celgene, FibroGen, Karyopharm Therapeutics, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Agios Pharmaceuticals, Incyte, Syndax Pharmaceuticals, Seagen, Daiichi-Sankyo, Astellas Pharma, Servier, Swedish Orphan Biovitrum, Sierra Oncology, Genentech, Daiichi Sankyo Europe
OpenAlex ID: W7148545871
FWCI:
Cites:
Cited by:
Related to: